Catalyst Wire Dossier Catalyst Wire Dossier

GSK1349572 (dolutegravir)

dolutegravir · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GSK1349572 (dolutegravir), covering 2013-07-04 to 2017-06-08. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers [Phase 1]

See pricing